Committed to being a leader in harnessing the power of the microbiome to help prevent, diagnose, and treat diseases C. DIFFICILE INFECTION OUR SCIENTIFIC PUBLICATIONS Latest News NEWS / 15 NOV 2021 Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2021 NEWS / 03 NOV 2021 Summit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical Research Executive Dr. Urte Gayko NEWS / 08 OCT 2021 Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors VIEW NEWS ARTICLES We are building a very differentiated company that focuses on bringing innovation to the treatment of high unmet medical needs by focusing on the cause of the condition and sparing the rest of the incredible ecosystem that is the human body. Precision-targeting agents will be the new standards of care because they benefit patients and healthcare providers by minimizing trauma while curing the disease, which, in turn, creates value for society and payers alike. Bob Duggan Chairman & Chief Executive Officer Partners BARDA Summit is proud to partner with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), as initially announced on September 11, 2017, on its Phase III Ri-CoDIFy trial program investigating ridinilazole for the treatment and reduction of recurrence of C. difficile infection. BARDA CARB-X Summit is proud to partner with CARB-X, as announced on May 18, 2021, to progress the development of its precision antibiotic candidate, SMT-738, through its IND-enabling and Phase Ia clinical trials for the treatment of highly-resistant CRE bacterial infections. CARB-X ABOUT SUMMIT THERAPEUTICS OUR VALUES OUR PROGRAMMES DISCUVA PLATFORM PUBLICATIONS INVESTOR CENTRE PRESS RELEASES REPORTS & FILINGS SHARE PRICE DATA CONTACT SOCIAL MEDIA PLATFORMS TWITTER LINKEDIN © 2021 SUMMIT THERAPEUTICS INC. TRADEMARKS, REGISTERED OR OTHERWISE, ARE THE PROPERTY OF THEIR RESPECTIVE OWNER(S). WEBSITE DESIGNED AND DEVELOPED BY CARR KAMASA DESIGN DISCLAIMER PRIVACY POLICY SITE MAP

PIPELINE HOME ∕ OUR PIPELINE ∕ PIPELINE Our Pipeline Discuva Platform DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 C. difficile infection (ridinilazole) Carbapenem-resistant Enterobacteriaceae (CRE) Infections (SMT-738) ABOUT SUMMIT THERAPEUTICS OUR VALUES OUR PROGRAMMES DISCUVA PLATFORM PUBLICATIONS INVESTOR CENTRE PRESS RELEASES REPORTS & FILINGS SHARE PRICE DATA CONTACT SOCIAL MEDIA PLATFORMS TWITTER LINKEDIN © 2021 SUMMIT THERAPEUTICS INC. TRADEMARKS, REGISTERED OR OTHERWISE, ARE THE PROPERTY OF THEIR RESPECTIVE OWNER(S). WEBSITE DESIGNED AND DEVELOPED BY CARR KAMASA DESIGN DISCLAIMER PRIVACY POLICY SITE MAP